Epizyme Inc. buy stratec
Start price
24.09.18
/
50%
€9.70
Target price
04.11.21
€23.45
Performance (%)
-55.86%
End price
05.11.21
€4.28
Summary
This prediction ended on 05.11.21 with a price of €4.28. The BUY prediction by stratec for Epizyme Inc. performed very badly with a performance of -55.86%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Epizyme Inc. | - | - | - | - |
| iShares Core DAX® | 4,57 % | 4,14 % | 7,35 % | 57,58 % |
| iShares Nasdaq 100 | 1,83 % | -1,64 % | 33,64 % | 88,08 % |
| iShares Nikkei 225® | -0,29 % | 2,47 % | 60,45 % | 76,67 % |
| iShares S&P 500 | 2,23 % | 0,71 % | 24,13 % | 66,11 % |
Comments by stratec for this prediction
In the thread Epizyme Inc. diskutieren
stratec stimmt dem Sentiment von 'Buy' zu
Oppenheimer's call:An annoncement of the partial clinical hold being lifted by FDA supports our outlook for tazemetostat. Tazemetostat is currently being studied in clinical programs in INI-1 negative tumors, synovial sarcomas, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and mesothelioma. While the partial clinical hold may have delayed enrollment in some studies, these are not currently factored into our outlook; therefore, the hold had little impact on our outlook. The news removes a regulatory overhang and supports our outlook for Epizyme.”
In the thread Trading Epizyme Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten